- Home
- III vs ABOS Comparison
III vs ABOS Comparison
Compare III & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- III
- ABOS
- Stock Information
- Founded
- III 2006
- ABOS 1996
- Country
- III United States
- ABOS United States
- Employees
- III N/A
- ABOS N/A
- Industry
- III Professional Services
- ABOS Biotechnology: Pharmaceutical Preparations
- Sector
- III Consumer Discretionary
- ABOS Health Care
- Exchange
- III Nasdaq
- ABOS Nasdaq
- Market Cap
- III 178.1M
- ABOS 99.1M
- IPO Year
- III 2007
- ABOS 2021
- Fundamental
- Price
- III $3.10
- ABOS $1.56
- Analyst Decision
- III Buy
- ABOS Strong Buy
- Analyst Count
- III 1
- ABOS 3
- Target Price
- III $3.75
- ABOS $9.33
- AVG Volume (30 Days)
- III 114.2K
- ABOS 379.4K
- Earning Date
- III 03-06-2025
- ABOS 11-12-2024
- Dividend Yield
- III 5.76%
- ABOS N/A
- EPS Growth
- III N/A
- ABOS N/A
- EPS
- III N/A
- ABOS N/A
- Revenue
- III $255,994,000.00
- ABOS N/A
- Revenue This Year
- III N/A
- ABOS N/A
- Revenue Next Year
- III N/A
- ABOS N/A
- P/E Ratio
- III N/A
- ABOS N/A
- Revenue Growth
- III N/A
- ABOS N/A
- 52 Week Low
- III $2.92
- ABOS $1.54
- 52 Week High
- III $4.82
- ABOS $5.09
- Technical
- Relative Strength Index (RSI)
- III 33.70
- ABOS 30.29
- Support Level
- III $3.01
- ABOS $1.69
- Resistance Level
- III $3.32
- ABOS $1.88
- Average True Range (ATR)
- III 0.09
- ABOS 0.13
- MACD
- III -0.03
- ABOS -0.00
- Stochastic Oscillator
- III 20.45
- ABOS 4.88
About III Information Services Group Inc.
Information Services Group Inc is a U.S.-based technology insight, market intelligence, and advisory services firm. It principally offers digital transformation services, such as automation and cloud & data analytics; managed governance; network carrier services; technology plan and operations design; changes management; market intelligence & technology research and analysis. It operates in one segment, fact-based sourcing advisory services. Its geographical segments are the Americas, Europe, and Asia-pacific, out of which maximum revenue is derived from Americas.
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.